The FDA granted orphan designation to a treatment of sickle cell disease being developed by Beam Therapeutics (BEAM), according to a post to the agency’s website.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BEAM:
- Beam Therapeutics receives orphan drug designation for BEAM-302
- Beam Therapeutics treatment of alpha-1 antitrypsin deficiency gets orphan status
- Beam Therapeutics announces FDA grants RMAT designation to BEAM-302
- Beam Therapeutics: Promising Gene Editing Advancements and Strategic Execution Reinforce Buy Rating
- Beam Therapeutics: Promising Pipeline and Financial Stability Justify Buy Rating